With reference to captioned subject find enclosed herewith Annual Report of the Company for the F.Y. 2024-25 Kindly take the same on your record.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Tejnaksh Healthcare Ltd has submitted its Annual Report for FY 2024-25 to BSE ahead of its 18th Annual General Meeting scheduled for September 27, 2025 at 3:00 PM via video conferencing. Key items on the AGM agenda include adoption of audited standalone and consolidated financial statements for the year ended March 31, 2025, re-appointment of Dr. Ashish Rawandale as Managing Director for a fresh 5-year term (from March 27, 2025 to March 27, 2030), and appointment of two new Independent Directors — Mr. Vijay Bhimsing Pawar and Mrs. Sunita Pawar — for 5-year terms effective September 30, 2025. The company also proposes appointing CS Nandish Dave as Secretarial Auditor for 5 years covering FY 2025-26 to FY 2029-30. The company operates the Institute of Urology in Dhule, Maharashtra, and is listed on BSE (Scrip Code: 539428).
This is a routine regulatory filing submitting the annual report ahead of the AGM. No material new financial numbers are disclosed in the cover document; investors should review the full annual report for actual performance metrics. The director re-appointments are procedural and unlikely to impact the stock price.